Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: Identification of novel cellular targets - Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9

Molecular Pharmacology

Volumn 79, Issue 1, 2011, Pages 185-196

  Debebe, Zufan ^a,b   Ammosova, Tatyana ^a   Breuer, Denitra ^a,b   Lovejoy, David B ^c   Kalinowski, Danuta S ^c   Karla, Pradeep K ^b   Kumar, Krishna ^b   Jerebtsova, Marina ^d   Ray, Patricio ^d   Kashanchi, Fatah ^e   Gordeuk, Victor R ^a   Richardson, Des R ^c   Nekhai, Sergei ^a,b  

^a HOWARD UNIVERSITY   (United States)

^b HOWARD UNIVERSITY   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 NITROBENZOYL)PYRIDINE 4 ALLYL 3 THIOSEMICARBAZONE; 2 (3 NITROBENZOYL)PYRIDINE 4 ETHYL 3 THIOSEMICARBAZONE; 2 BENZOYLPYRIDINE 4 ALLYL 3 THIOSEMICARBAZONE; 2 BENZOYLPYRIDINE 4 ETHYL 3 THIOSEMICARBAZONE; 2 BENZOYLPYRIDINE 4 METHYL 3 THIOSEMICARBAZONE; 2 BENZOYLPYRIDINE 4 PHENYL 3 THIOSEMICARBAZONE; 2 BENZOYLPYRIDINE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; 2 BENZOYLPYRIDINE THIOBENZOYLHYDRAZONE; 2 BENZOYLPYRIDINE THIOSEMICARBAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE ISONICOTINOYLHYDRAZONE; 4 AMINO 6 HYDRAZINO 7 BETA DEXTRO RIBOFURANOSYL 7H PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; DEFERASIROX; DI 2 PYRIDYLKETONE 2 METHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4 ALLYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4 PHENYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE THIOBENZOYLHYDRAZONE; DI 2 PYRIDYLKETONE THIOSEMICARBAZONE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON CHELATING AGENT; ROSCOVITINE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; HEK293 CELLS; HIV-1; HUMANS; IRON; IRON CHELATING AGENTS; THIOSEMICARBAZONES; TRANSCRIPTION, GENETIC;

EID: 78651341949     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069062     Document Type: Article

References (40)

1. Agbottah E, de La Fuente C, Nekhai S, Barnett A, Gianella-Borradori A, Pumfery A, and Kashanchi F (2005) Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem 280:3029-3042.
2. Ammosova T, Berro R, Kashanchi F, and Nekhai S (2005) RNA interference directed to CDK2 inhibits HIV-1 transcription. Virology 341:171-178.
3. Barthelme D, Scheele U, Dinkelaker S, Janoschka A, Macmillan F, Albers SV, Driessen AJ, Stagni MS, Bill E, Meyer-Klaucke W, et al. (2007) Structural organization of essential iron-sulfur clusters in the evolutionarily highly conserved ATP-binding cassette protein ABCE1. J Biol Chem 282:14598-14607.
4. Becker EM, Lovejoy DB, Greer JM, Watts R, and Richardson DR (2003) Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br J Pharmacol 138:819-830.
5. Berthet C, Aleem E, Coppola V, Tessarollo L, and Kaldis P (2003) Cdk2 knockout mice are viable. Curr Biol 13:1775-1785.
6. Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, Price DH, and Maury W (2007) Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4:47.
7. Butera ST, Roberts BD, Lam L, Hodge T, and Folks TM (1994) Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. J Virol 68:2726-2730.
8. Chun RF, Semmes OJ, Neuveut C, and Jeang KT (1998) Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 72:2615-2629.
9. Debebe Z, Ammosova T, Jerebtsova M, Kurantsin-Mills J, Niu X, Charles S, Richardson DR, Ray PE, Gordeuk VR, and Nekhai S (2007) Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology 367:324-333.
10. Drakesmith H and Prentice A (2008) Viral infection and iron metabolism. Nat Rev Microbiol 6:541-552.
11. Fu D and Richardson DR (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110:752-761.
12. Fu DX, Kuo YL, Liu BY, Jeang KT, and Giam CZ (2003) Human T-lymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 278:1487-1493.
13. Gao J and Richardson DR (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98:842-850.
14. Georgiou NA, van der Bruggen T, Oudshoorn M, Hider RC, Marx JJ, and van Asbeck BS (2002) Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. Eur J Clin Invest 32 (Suppl 1):91-96.
15. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, and van Asbeck BS (2000) Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis 181:484-490.
16. Gómez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, Alcamí J, and López-Cabrera M (2001) The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem 276:35435-35443.
17. Gordeuk VR, Delanghe JR, Langlois MR, and Boelaert JR (2001) Iron status and the outcome of HIV infection: an overview. J Clin Virol 20:111-115.
18. He J and Landau NR (1995) Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J Virol 69:4587-4592.
19. Hershko C (1994) Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol 7:965-1000.
20. Hoque M, Hanauske-Abel HM, Palumbo P, Saxena D, D'Alliessi Gandolfi D, Park MH, Pe'ery T, and Mathews MB (2009) Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 6:90.
21. Jochmann R, Thurau M, Jung S, Hofmann C, Naschberger E, Kremmer E, Harrer T, Miller M, Schaft N, and Stürzl M (2009) O-linked N- acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J Virol 83:3704-3718.
22. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV, and Richardson DR (2007) Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 50:3716-3729.
23. Kim YS, Kang KR, Wolff EC, Bell JK, McPhie P, and Park MH(2006) Deoxyhypusine hydroxylase is a Fe(II)-dependent, HEAT-repeat enzyme. Identification of amino acid residues critical for Fe(II) binding and catalysis [corrected]. J Biol Chem 281:13217-13225.
24. Lucas JJ, Szepesi A, Domenico J, Takase K, Tordai A, Terada N, and Gelfand EW (1995) Effects of iron-depletion on cell cycle progression in normal human T lymphocytes: selective inhibition of the appearance of the cyclin A-associated component of the p33cdk2 kinase. Blood 86:2268-2280.
25. Michels AA and Bensaude O (2008) RNA-driven cyclin-dependent kinase regulation: when CDK9/cyclin T subunits of P-TEFb meet their ribonucleoprotein partners. Biotechnol J 3:1022-1032.
26. Nekhai S, Bhat UG, Ammosova T, Radhakrishnan SK, Jerebtsova M, Niu X, Foster A, Layden TJ, and Gartel AL (2007) A novel anticancer agent ARC antagonizes HIV-1 and HCV. Oncogene 26:3899-3903.
27. Nekhai S and Jeang KT (2006) Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol 1:417-426.
28. Pahl PM, Reese SM, and Horwitz LD (2007) A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells. J Exp Ther Oncol 6:193-200.
29. Pahl PM, Yan XD, Hodges YK, Rosenthal EA, Horwitz MA, and Horwitz LD (2000) An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J Biol Chem 275:17821-17826.
30. Papadopoulos NG, Dedoussis GV, Spanakos G, Gritzapis AD, Baxevanis CN, and Papamichail M (1994) An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods 177:101-111.
31. Porter JB (2006) Deferasirox: An effective once-daily orally active iron chelator. Drugs Today (Barc) 42:623-637.
32. Satyanarayana A, Hilton MB, and Kaldis P (2008) p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol Biol Cell 19:65-77.
33. Traoré HN and Meyer D (2004) The effect of iron overload on in vitro HIV-1 infection. J Clin Virol 31 (Suppl 1):S92-S98.
34. Tsimberidou AM, Alvarado Y, and Giles FJ (2002) Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2:437-448.
35. West MJ, Lowe AD, and Karn J (2001) Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol 75:8524-8537.
36. Whitnall M, Howard J, Ponka P, and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901-14906.
37. Xie DX, Yao J, Zhang P, Li XL, Feng YD, Wu JH, Tao DD, Hu JB, and Gong JP (2008) Are progenitor cells pre-programmed for sequential cell cycles not requiring cyclins D and E and activation of Cdk2? Cell Prolif 41:265-278.
38. Yedavalli VS, Benkirane M, and Jeang KT (2003) Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 278:6404-6410.
39. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458.
40. Zimmerman C, Klein KC, Kiser PK, Singh AR, Firestein BL, Riba SC, and Lingappa JR. Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature 415(6867):88-92, 2002.